Search the site

Department

Rehabilitation Medicine

Post-stroke recovery, TBI/post-concussion, Long COVID, fibromyalgia

0 FDA-approved 4 research

Rehabilitation Medicine applies HBOT as an adjunct in the recovery phase — supporting functional recovery and neuroplasticity after neurological injury and in chronic disabling conditions. The evidence here is emerging and investigational: HBOT is studied as a complement to, not a replacement for, standard rehabilitation. Applications span chronic post-stroke recovery, traumatic brain injury and post-concussion syndrome, Long COVID, and fibromyalgia.

HBOT Applications

Investigational / Preclinical Level B

Chronic Post-Stroke Recovery

A prospective randomised trial in patients 6–36 months after stroke reported improved neurological function after 40 HBOT sessions at 2 ATA, with gains correlating with SPECT brain-activity changes (Efrati 2013). An independent feasibility RCT combining HBOT with an exercise and mental-imagery rehabilitation programme found the combined approach safe and feasible, with trends toward improved upper-limb motor function (Schiavo 2020). Investigational; not FDA-approved.

Protocol

Pressure

2 ATA

Duration

90 min

Sessions

40

Frequency

Once daily, 5×/week

Evidence basis: Efrati 2013 (RCT); Schiavo 2020 (feasibility RCT)

References: 49 50
Investigational / Preclinical Level B (contested)

Traumatic Brain Injury / Post-Concussion Recovery

Evidence is mixed. Chronic-phase trials report benefit: a crossover RCT in adults with prolonged post-concussion syndrome 1–5 years after mild TBI showed cognitive and quality-of-life improvement with SPECT correlates (Boussi-Gross 2013), and a sham-controlled, double-blind RCT in children with persistent post-concussion syndrome showed cognitive and behavioural improvement with MRI microstructural correlates (Hadanny 2022). However, sham-controlled trials in military personnel with mild TBI found HBOT and a low-pressure-air control improving similarly, without a clear HBOT-specific benefit (Walker/Cifu 2014), and a critical appraisal argues the apparent effect may reflect a participation effect, amid unresolved debate over whether the low-pressure "sham" is itself biologically active (Bennett 2018). Investigational; not FDA-approved.

Protocol

Pressure

2 ATA

Duration

60 – 90 min

Sessions

40 – 60

Frequency

Once daily, 5×/week

Evidence basis: Mixed RCT evidence (Boussi-Gross 2013; Hadanny 2022; Walker/Cifu 2014)

Investigational / Preclinical Level B

Long COVID

Relevant to rehabilitation for its fatigue, cognitive and functional-recovery dimensions. See the Long COVID indication for the full evidence and protocol.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

40

Frequency

5×/week

Evidence basis: Zilberman-Itskovich et al., 2022 (RCT)

Investigational / Preclinical Level B

Fibromyalgia

Relevant to rehabilitation for chronic pain and functional impairment. See the Fibromyalgia indication for the full evidence and protocol.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

40

Frequency

5×/week

Evidence basis: Efrati et al., 2015 (prospective controlled trial)

Last updated: